Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive rats
Hypertension frequently results in severe complications in cardiovascular system and histopathological changes in the heart. To better understand the cellular processes and signaling pathways responsible for the proper functioning of the heart, we decided to check whether doxazosin affects the density of structures containing S100A6 and atrial natriuretic factor in the heart of spontaneously hypertensive rats. The aim of this study is to find differences in the density of the structures containing S100A6 and atrial natriuretic factor in the heart of spontaneously hypertensive rats treated with doxazosin compared to untreat...
Source: Experimental Biology and Medicine - January 28, 2016 Category: Research Authors: Kasacka, I., Piotrowska, Z., Filipek, A., Majewski, M. Tags: Anatomy & amp;amp; Pathology Source Type: research
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men.
CONCLUSIONS: When baseline PSA level was greater than 4 ng/mL, the doubling rule could be used for screening. When baseline PSA level was less than 4 ng/Ml, the doubling rule might not be an accurate predictor. We can use the PSA rise from nadir or proPSA to predict prostate cancer.
PMID: 26754047 [PubMed - as supplied by publisher] (Source: Aging Clinical and Experimental Research)
Source: Aging Clinical and Experimental Research - January 11, 2016 Category: Geriatrics Authors: Xu D, Ding J, Zhu Y, Qian X, Duan L, Qi J Tags: Aging Clin Exp Res Source Type: research
Effects of the inverse alpha agonist doxazosin in allergic rhinitis
ConclusionsThere was a disconnect between single and chronic dosing effects of doxazosin for nasal symptoms, oxymetazoline response and cardiovascular outcomes, in turn suggesting alpha‐1 receptor up‐regulation .(www . clinicaltrials. gov # NCT01946035)This article is protected by copyright. All rights reserved. (Source: Clinical and Experimental Allergy)
Source: Clinical and Experimental Allergy - January 6, 2016 Category: Allergy & Immunology Authors: Arvind Manoharan, Ashley E. Morrison, Brian J. Lipworth Tags: Original Article ‐Asthma and Rhinitis Source Type: research
Reappraisal of Antihypertensive Medicine Doxazosin and Carvedilol as a Potential Therapeutic for Hepatic Fibrosis.
Authors: Paik YH
PMID: 26696027 [PubMed - in process] (Source: Gut and Liver)
Source: Gut and Liver - December 25, 2015 Category: Gastroenterology Tags: Gut Liver Source Type: research
Synthesis, vasorelaxant activity and 2D-QSAR study of some novel pyridazine derivatives.
Abstract
Novel 3,6-disubstituted pyridazines were synthesized by facile method and screened for their vasorelaxant properties utilizing isolated thoracic rat aortic rings. Compounds 8a and 11a exerted potent vasorelaxant activity (IC50 = 198 and 177 μM, respectively) relative to doxazosin mesylate (used reference standard, IC50 = 226 μM), that, they may represent promising hits for treatment of cardiovascular disorders. The observed activity was validated by a statistically significant QSAR model (N = 32, n = 6, R(2) = 0.811782, R(2)cvOO = 0.7153, R(2)cvMO = 0.7209, F = 17.9708, s(2) =...
Source: European Journal of Medicinal Chemistry - December 12, 2015 Category: Chemistry Authors: George RF, Saleh DO Tags: Eur J Med Chem Source Type: research
Direct Vasodilators and Sympatholytic Agents
Direct vasodilators and sympatholytic agents were some of the first antihypertensive medications discovered and utilized in the past century. However, side effect profiles and the advent of newer antihypertensive drug classes have reduced the use of these agents in recent decades. Outcome data and large randomized trials supporting the efficacy of these medications are limited; however, in general the blood pressure-lowering effect of these agents has repeatedly been shown to be comparable to other more contemporary drug classes. Nevertheless, a landmark hypertension trial found a negative outcome with a doxazosin-based re...
Source: Journal of Cardiovascular Pharmacology and Therapeutics - December 10, 2015 Category: Cardiology Authors: McComb, M. N., Chao, J. Y., Ng, T. M. H. Tags: Cardiovascular Pharmacology Core Reviews Source Type: research
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial
We examined first (incident) reports of selected adverse experiences with time associated with medical therapy in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. (Source: The Journal of Urology)
Source: The Journal of Urology - December 8, 2015 Category: Urology & Nephrology Authors: Steven A. Kaplan, Jeannette Y. Lee, Alan G. Meehan, John W. Kusek Tags: Adult Urology Source Type: research
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride, and Combination Therapy in Men with Benign Prostatic Hyperplasia: the Medical Therapy of Prostatic Symptoms (MTOPS) Trial
We examined first (incident) reports of selected adverse experiences (AEs) over time associated with medical therapy in men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). (Source: The Journal of Urology)
Source: The Journal of Urology - December 8, 2015 Category: Urology & Nephrology Authors: Steven A. Kaplan, Jeannette Y. Lee, Alan G. Meehan, John W. Kusek Source Type: research
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
This is a double-blind, placebo-controlled, crossover trial in patients with resistant hypertension that were taking maximally tolerated doses of 3 or more drugs. The authors found that the average reduction in home systolic blood pressure by spironolactone was superior to placebo (-8•70 mm Hg [95% CI -9•72 to -7•69]; p<0•0001), superior to the mean of the other two active treatments (doxazosin and bisoprolol; -4•26 [-5•13 to -3•38]; p<0•0001), and superior when compared with the individual treatments; versus doxazosin (-4•03 [-5•04 to -3•02]; p<0•0001) and versus bisoprolol (-4•48 [-5•...
Source: Nephrology Now - November 30, 2015 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Nephrology Clinical Trial Results Hypertension Source Type: research
The effects of alpha 1-adrenoceptor-blockade by doxazosin and angiotensin converting enzyme-inhibition by Ramipril on central and brachial blood pressure and vascular reactivity in mild-to-moderate hypertension: The doxazosin ramipril study
Objectives: To study whether inhibition of the renin-angiotensin-aldosterone system has effects on vascular function beyond blood pressure (BP) reduction alone. (Source: Artery Research)
Source: Artery Research - November 24, 2015 Category: Cardiology Authors: Andreas Jekell, Majid Kalani, Thomas Kahan Source Type: research
Effects of alpha1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review.
Authors: Creta M, Bottone F, Sannino S, Maisto E, Franco M, Mangiapia F, La Rocca R, Imperatore V, Longo N, Vivaldi O, Fusco F
Abstract
α1-adrenergic receptors blockers (ABs) are recommended as first-line medical therapy in men with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Enlargement (LUTS/BPE). Available ABs include: terazosin, doxazosin, tamsulosin, naftopidil, alfuzosin and silodosin. These agents have different profiles of selectivity for α1-adrenergic receptors subtypes. All these agents are efficacious in improving both storage and voiding LUTS. In recent years the efficacy of A...
Source: Minerva Urologica e Nefrologica - November 19, 2015 Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion.
Conclusions: Taken together, these results suggest that the decrease in collagen type I following treatment with doxazosin or carvedilol is achieved by decreasing the profibrotic activities of TGF-β via the blockage of α1- and β-adrenergic receptor. Consequently, a diminution of fibrotic tissue in the CCl4-induced model of cirrhosis is achieved.
PMID: 26573293 [PubMed - as supplied by publisher] (Source: Gut and Liver)
Source: Gut and Liver - November 18, 2015 Category: Gastroenterology Tags: Gut Liver Source Type: research
Abstract P153: Impact of Antibiotic Treatment on Antihypertensive Drug Adherence [Session Title: Clinical /Blood Pressure/Therapeutic/Other 1]
Conclusion: A single course of antibiotic therapy can have a sustained adverse impact on antihypertensive drug adherence over the following year. The impact of this on BP control and outcomes need to be further study. (Source: Hypertension)
Source: Hypertension - November 3, 2015 Category: Cardiology Authors: Kassi, M., McCallum, L., Muir, S., Touyz, R., Dominiczak, A. F., Padmanabhan, S. Tags: Session Title: Clinical /Blood Pressure/Therapeutic/Other 1 Source Type: research
Analysis of aged human serum albumin affinity for doxazosin.
Abstract
Structural changes of human serum albumin (HSA) caused by old age and coexisting diseases result in differences in the binding of doxazosin (DOX). DOX is a postsynaptic α1- adrenoreceptor antagonist used for treatment of hypertension and benigin prostatic hyperplasia. In elderly people suffering from various renal or hepatic diseases the significant portion of N-form of human serum albumin (normal) is converted to A-form (aged). The differences in binding of doxazosin to N- and A-form of albumin are an important factor, which may determines therapeutic dosage and toxicity of the test drug. To ind...
Source: Current Protein and Peptide Science - November 1, 2015 Category: Biochemistry Authors: Mariola C, Joanna RZ, Jadwiga P, Bartosz P, Anna S Tags: Curr Protein Pept Sci Source Type: research
Efficacy and tolerability of doxazosin in psychostimulant-dependent patients
Aims: Examine safety and efficacy of doxazosin (DOX) extended release (ER) (8mg/d) vs placebo (PLA) to reduce methamphetamine (METH) and cocaine (COC) use in METH and COC dependent (dep) volunteers over 10-wk pilot outpatient trial. (Source: Drug and Alcohol Dependence)
Source: Drug and Alcohol Dependence - November 1, 2015 Category: Addiction Authors: Michael J. Mancino, Janette McGaugh, Jeff D. Thostenson, Joseph Guise, Thomas Kosten, Alison Oliveto Source Type: research
